Blood Glucose Monitoring System includes Meter, vial of 10 strips, 2mL bottle of
Blood Glucose Monitoring System includes Meter, vial of 10 strips, 2mL bottle of Control 1, lancing device, 10 lancets (30G)
JJX,CGA,NBW
Single (specified) analyte controls (assayed and unassayed),GLUCOSE OXIDASE, GLU
Single (specified) analyte controls (assayed and unassayed),GLUCOSE OXIDASE, GLUCOSE,SYSTEM, TEST, BLOOD GLUCOSE, OVER THE COUNTER
Blood Glucose Monitoring System includes Meter, vial of 10 strips, 2mL bottle of
Blood Glucose Monitoring System includes Meter, vial of 10 strips, 2mL bottle of Control 1, lancing device, 10 lancets (30G)
NBW,JJX,CGA
SYSTEM, TEST, BLOOD GLUCOSE, OVER THE COUNTER,Single (specified) analyte control
SYSTEM, TEST, BLOOD GLUCOSE, OVER THE COUNTER,Single (specified) analyte controls (assayed and unassayed),GLUCOSE OXIDASE, GLUCOSE
Blood Glucose Monitoring System includes Meter, vial of 10 strips, 2mL bottle of
Blood Glucose Monitoring System includes Meter, vial of 10 strips, 2mL bottle of Control 1, lancing device, 10 lancets (30G)
JJX,NBW,CGA
Single (specified) analyte controls (assayed and unassayed),SYSTEM, TEST, BLOOD
Single (specified) analyte controls (assayed and unassayed),SYSTEM, TEST, BLOOD GLUCOSE, OVER THE COUNTER,GLUCOSE OXIDASE, GLUCOSE
Blood Glucose Meter, vial of 10 strips, 2mL bottle of Control 1, lancing device,
Blood Glucose Meter, vial of 10 strips, 2mL bottle of Control 1, lancing device, 10 lancets (30G)
CGA,NBW,JJX
GLUCOSE OXIDASE, GLUCOSE,System, test, blood glucose, over the counter,Single (s
GLUCOSE OXIDASE, GLUCOSE,System, test, blood glucose, over the counter,Single (specified) analyte controls (assayed and unassayed)
On Call Express Mobile Blood Glucose Monitoring System
DIAZO (COLORIMETRIC), NITRITE (URINARY, NON-QUANT),REFRACTOMETER FOR CLINICAL US
DIAZO (COLORIMETRIC), NITRITE (URINARY, NON-QUANT),REFRACTOMETER FOR CLINICAL USE,DIAZONIUM COLORIMETRY, UROBILINOGEN (URINARY, NON-QUANT.),INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.),BLOOD, OCCULT, COLORIMETRIC, IN URINE,AZO-DYES, COLORIMETRIC, BILIRUBIN & ITS CONJUGATES (URINARY, NON-QUANT.)
BLOOD, OCCULT, COLORIMETRIC, IN URINE,DIAZO (COLORIMETRIC), NITRITE (URINARY, NO
BLOOD, OCCULT, COLORIMETRIC, IN URINE,DIAZO (COLORIMETRIC), NITRITE (URINARY, NON-QUANT),METHOD, ENZYMATIC, GLUCOSE (URINARY, NON-QUANTITATIVE),TEST, URINE LEUKOCYTE,INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.)
INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.),TEST, URINE LEUKOCYTE
INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.),TEST, URINE LEUKOCYTE,BLOOD, OCCULT, COLORIMETRIC, IN URINE,DIAZO (COLORIMETRIC), NITRITE (URINARY, NON-QUANT)
BLOOD, OCCULT, COLORIMETRIC, IN URINE,INDICATOR METHOD, PROTEIN OR ALBUMIN (URIN
BLOOD, OCCULT, COLORIMETRIC, IN URINE,INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.),METHOD, ENZYMATIC, GLUCOSE (URINARY, NON-QUANTITATIVE),TEST, URINE LEUKOCYTE
INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.),BLOOD, OCCULT, COLORI
INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.),BLOOD, OCCULT, COLORIMETRIC, IN URINE,METHOD, ENZYMATIC, GLUCOSE (URINARY, NON-QUANTITATIVE),DYE-INDICATOR, PH (URINARY, NON-QUANT.)
REFRACTOMETER FOR CLINICAL USE,INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NO
REFRACTOMETER FOR CLINICAL USE,INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.),DYE-INDICATOR, PH (URINARY, NON-QUANT.),METHOD, ENZYMATIC, GLUCOSE (URINARY, NON-QUANTITATIVE)
DIAZO (COLORIMETRIC), NITRITE (URINARY, NON-QUANT),INDICATOR METHOD, PROTEIN OR
DIAZO (COLORIMETRIC), NITRITE (URINARY, NON-QUANT),INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.),TEST, URINE LEUKOCYTE,METHOD, ENZYMATIC, GLUCOSE (URINARY, NON-QUANTITATIVE)
NITROPRUSSIDE, KETONES (URINARY, NON-QUANT.),INDICATOR METHOD, PROTEIN OR ALBUMI
NITROPRUSSIDE, KETONES (URINARY, NON-QUANT.),INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.),METHOD, ENZYMATIC, GLUCOSE (URINARY, NON-QUANTITATIVE)
METHOD, ENZYMATIC, GLUCOSE (URINARY, NON-QUANTITATIVE),INDICATOR METHOD, PROTEIN
METHOD, ENZYMATIC, GLUCOSE (URINARY, NON-QUANTITATIVE),INDICATOR METHOD, PROTEIN OR ALBUMIN (URINARY, NON-QUANT.)
QuickProfile™ 2019-nCoV IgG/IgM Test Card is an immunochromatography based one s
QuickProfile™ 2019-nCoV IgG/IgM Test Card is an immunochromatography based one step in vitro test. It is designed for the rapid qualitative determination of IgG and IgM antibodies to the 2019 novel coronavirus (2019-nCoV, SARS-CoV-2) in human serum, plasma, or whole blood. QuickProfile™ 2019-nCoV IgG/IgM Test Card is a supplemental rapid screening tool for symptomatic or asymptomatic carriers of the virus.
The Access SARS-CoV-2 IgG II QC is intended for monitoring system performance of
The Access SARS-CoV-2 IgG II QC is intended for monitoring system performance of the Access SARS-CoV-2 IgG II assay using the Access Immunoassay Systems only.The Access SARS-CoV-2 IgG II QC are only for use under the Food and Drug Administration's Emergency Use Authorization.
The Access SARS-CoV-2 IgG II Calibrators are intended to calibrate the Access SA
The Access SARS-CoV-2 IgG II Calibrators are intended to calibrate the Access SARS-CoV-2 IgG II assay for the in vitro semi-quantitative and qualitative detection of SARS-CoV-2 IgG antibodies in human plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, and sodium citrate) for use on the Access Immunoassay Systems only.The Access SARS-CoV-2 IgG II calibrators are only for use under the Food and Drug Administration's Emergency Use Authorization.
The Access SARS-CoV-2 IgG II assay is a paramagnetic particle, chemiluminescent
The Access SARS-CoV-2 IgG II assay is a paramagnetic particle, chemiluminescent immunoassay intended for the semi-quantitative and qualitative detection of IgG antibodies to SARS-CoV-2 in human plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, and sodium citrate). The Access SARS-CoV-2 IgG II assay is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The Access SARS-CoV-2 IgG II should not be used to diagnose or exclude acute SARS-CoV-2 infection. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests.The Access SARS-CoV-2 IgG II assay is only for use under the Food and Drug Administration's Emergency Use Authorization.
The Access SARS-CoV-2 IgG QC is intended for monitoring system performance of th
The Access SARS-CoV-2 IgG QC is intended for monitoring system performance of the Access SARS-CoV-2 IgG assay. The Access SARS-CoV-2 IgG QC is for use on the Access Family of Immunoassay Systems only.The Access SARS-CoV-2 IgG QC are only for use under the Food and Drug Administration's Emergency Use Authorization.
The Access SARS-CoV-2 IgG Calibrators are intended to calibrate the Access SARS-
The Access SARS-CoV-2 IgG Calibrators are intended to calibrate the Access SARS-CoV-2 IgG assay for the in vitro qualitative detection of SARS-CoV-2 IgG antibodies in human serum, serum separator tubes and plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, and sodium citrate) for use on the Access Family of Immunoassay Systems only. The Access SARS-CoV-2 IgG Calibrators are only for use under the Food and Drug Administration's Emergency Use Authorization.
The Access SARS-CoV-2 IgG assay is a paramagnetic particle, chemiluminescent imm
The Access SARS-CoV-2 IgG assay is a paramagnetic particle, chemiluminescent immunoassay intended for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum, serum separator tubes and plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, and sodium citrate). The Access SARS-CoV-2 IgG assay is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests.The Access SARS-CoV-2 IgG assay is only for use under the Food and Drug Administration's Emergency Use Authorization.
The Access SARS-CoV-2 IgM QC is intended for monitoring system performance of th
The Access SARS-CoV-2 IgM QC is intended for monitoring system performance of the Access SARS-CoV-2 IgM assay. The Access SARS-CoV-2 IgM QC is for use on the Access Family of Immunoassay Systems only.The Access SARS-CoV-2 IgM QC are only for use under the Food and Drug Administration's Emergency Use Authorization.
The Access SARS-CoV-2 IgM Calibrators are intended to calibrate the Access SARS-
The Access SARS-CoV-2 IgM Calibrators are intended to calibrate the Access SARS-CoV-2 IgM assay for the in vitro qualitative detection of SARS-CoV-2 IgM antibodies in human serum, serum separator tubes and plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, sodium citrate) for use on the Access Family of Immunoassay Systems only.The Access SARS-CoV-2 IgM calibrators are only for use under the Food and Drug Administration's Emergency Use Authorization.
The Access SARS-CoV-2 IgM is a paramagnetic particle, chemiluminescent immunoass
The Access SARS-CoV-2 IgM is a paramagnetic particle, chemiluminescent immunoassay intended for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum, serum separator tubes and plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, sodium citrate). The Access SARS-CoV-2 IgM is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The Access SARS-CoV-2 IgM should not be used to diagnose acute SARS-CoV-2 infection. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests.The Access SARS-CoV-2 IgM assay is only for use under the Food and Drug Administration's Emergency Use Authorization.